Published in Cancer Weekly, April 21st, 1997
"These procedures provide novel powerful cell-free tumor vaccines," suggested Walter Schmidt and colleagues of the Research Institute of Molecular Pathology, Vienna, Austria.
Schmidt et al. reported in vivo data supporting this contention in the Proceedings of the National Academy of Sciences ("Cell-Free Tumor Antigen Peptide-Based Cancer Vaccines," PNAS, 1997;94:3262-7).
The Austrian researchers call their technique for importing short peptide ligands into antigen-presenting cells "transloading."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.